Medical

Cover Focus

Drug Delivery: Pearls and Projections

Contributors comment on the present use and future potential of this treatment approach.

Malik Y. Kahook, MD; Jason Bacharach, MD; Courtney Bovee, MD; Savak Teymoorian, MD, MBA; John P. Berdahl, MD; Constance Okeke, MD, MSCE; and Steven R. Sarkisian Jr, MD

Cover Focus

The Transformative Impact of Global Ophthalmology

Insight into the rewards and challenges of global ophthalmology.

Aaron Goh Qi Yang, MBBS, and Cathleen M. McCabe, MD

Cover Focus

Ongoing Medical Relief in Jordan

Providing care for vulnerable refugee populations.

Zaiba Malik, MD

The Literature

Lessons in Nonsurgical Glaucoma Management

Should SLT be performed as the initial treatment for glaucoma and ocular hypertension?

Jiun Lap Do, MD, PhD, and Naimul Alam, MD

Residents & Fellows

Systemic Ocular Antihypertensive Medications

A review of hyperosmotic agents and carbonic anhydrase inhibitors.

Galia Deitz, MD, MPH

Peer Review

Management of Ocular Surface Disease Before and After Glaucoma Surgery

OSD in patients who have glaucoma is best managed with a methodical, proactive approach to diagnosis and treatment.

Laura A. Voicu, MD

Case Files

Recurrent Hyphema

Jacob Brubaker, MD; Sahar Bedrood, MD, PhD; and Xiongfei Liu, MD

Case Files

Intolerant of All Glaucoma Medications

What is the next step when glaucoma is progressing and IOP is elevated after laser trabeculoplasty?

Steven R. Sarkisian Jr, MD; Sahar Bedrood, MD, PhD; Nathan M. Radcliffe, MD; and Manjool Shah, MD

Integrating DURYSTA (bimatoprost intracameral implant) Into Your Practice: Insights From Colleagues

Arsham Sheybani, MD; Preeya Gupta, MD; Manjool Shah, MD; Jacob Brubaker, MD; and George Tanaka, MD

Pharma Focus

Side Effects of Glaucoma Medications

Providers must be aware of the common and uncommon side effects associated with each agent and class of medication.

Eileen Chang, MD; Soshian Sarrafpour, MD; and Christopher C. Teng, MD

Pharma Focus

Novel Glaucoma Medications: From Clinical Trials to Clinical Experience

Insights into the use of these treatments as additive therapies for IOP reduction.

Vladislav P. Bekerman, MD, MBA, and Albert S. Khouri, MD

Case Files

Active Glaucoma or an Old Insult?

Clinicians discuss the diagnosis and therapeutic considerations.

Devesh K. Varma, MD, FRCSC; Reena A. Garg, MD; and Michael D. Greenwood, MD

Glaucoma Pipeline Poster

Glaucoma Pipeline 2021: A View Into Ongoing Innovation

The Pipeline

iDose: An Intraocular Drug-Eluting Delivery Device for Glaucoma

A closer look at the device’s implantation, clinical trial findings, and outstanding questions.

Mitch Ibach, OD, FAAO

Case Files

Iatrogenic Cyclodialysis Cleft

After closure of the cleft, this patient experienced intense pain and an extreme elevation in IOP that was refractory to medical management.

John T. Lind, MD, MS, and Leonard K. Seibold, MD

Technical Talk

Repetitive Transorbital Alternating Current Stimulation

Could this noninvasive therapy be used to activate viable but poorly functional retinal ganglion cells in patients with glaucoma?

Joel Kovoor, BS; Joseph F. Panarelli, MD; and Joel S. Schuman, MD

The Literature

Blunting IOP Spikes After Cataract Surgery

Options for minimizing severe IOP increases after phacoemulsification in patients with glaucoma.

Eiyass Albeiruti, MD

Cover Focus

Implementing Advances in Drug Delivery

How do new treatment options fit in with existing therapeutic strategies?

I. Paul Singh, MD

Cover Focus

Sustained Drug Delivery: Real-World Experience

Surgeons describe their initial cases and the insights gained using a new pharmaceutical solution for glaucoma.

Gagan Sawhney, MD; Roman Krivochenitser, MD; Blake K. Williamson, MD, MPH; and Steven R. Sarkisian Jr, MD